These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9889704)

  • 21. [Pertinence of animal and human models in the evaluation of ventricular anti-arrhythmia agents].
    Funck-Brentano C; Le Heuzey JY
    Arch Mal Coeur Vaiss; 1991 Feb; 84 Spec No 2():15-20. PubMed ID: 1726994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The pro-arrhythmia effects of anti-arrhythmia agents--theoretical and clinical aspects].
    Steinbeck G
    Z Kardiol; 1992; 81 Suppl 4():139-43. PubMed ID: 1290290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electrophysiologic effects of nibentan (HE-11) on canine cardiac tissue.
    Anyukhovsky EP; Sosunov EA; Rosen MR
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1137-46. PubMed ID: 9067296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The pharmacology of the new combined anti-arrhythmia preparation metatsizin].
    Kaverina NV; Chichkanov GG; Bugriĭ EM; Vititnova MB; Tolmacheva EA; Turilova AI; Kryzhanovskiĭ SA; Lyskovtsev VV; Rodionov AP; Beloborodov VL
    Eksp Klin Farmakol; 1998; 61(2):33-6. PubMed ID: 9621171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparative study of the anti-arrhythmic activity of cardiocyclide and nibentan in hypersympathotonia and acute myocardial ischemia].
    Vititnova MB; Kryzhanovskiĭ SA; Kaverina NV
    Eksp Klin Farmakol; 2002; 65(2):24-6. PubMed ID: 12109286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Risks and side effects in treatment of supraventricular tachycardia].
    Lüderitz B
    Z Gesamte Inn Med; 1993 Sep; 48(9):459-65. PubMed ID: 8212752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical significance of the use-dependent sodium channel block and reverse use-dependent potassium channel block of class I and class III antiarrhythmic agents and their values to predict drug efficacy].
    Sadanaga T; Ogawa S; Okada Y; Handa S
    Jpn Circ J; 1992; 56 Suppl 5():1474-6. PubMed ID: 1337923
    [No Abstract]   [Full Text] [Related]  

  • 28. [Cardiac effects of the class III antiarrhythmic drugs amiodarone and nibentan].
    Ugdyzhekova DS; Afanas'ev SA; Lukavskaia IA; Popov SV
    Fiziol Cheloveka; 2005; 31(4):113-8. PubMed ID: 16122045
    [No Abstract]   [Full Text] [Related]  

  • 29. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
    Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Azimilide dihydrochloride: a unique class III antiarrhythmic agent.
    Tran HT
    Heart Dis; 1999; 1(2):114-6. PubMed ID: 11720612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The anti-arrhythmia activity and effect on the heart conduction system of the new anti-arrhythmia preparation bonnecor].
    Sokolov SF; Golitsyn SP; Malakhov VI; Bankuzov VA; Koltunova MI; Golitsyn LS
    Farmakol Toksikol; 1990; 53(3):57-60. PubMed ID: 2387385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter.
    Rahme MM; Ungab GA; Wadhwa M; Al-Kandari F; Yao B; Gupta A; Lee K; Kim HY; Feld GK
    J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):297-306. PubMed ID: 11584336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electrophysiologic evaluation of antiarrhythmic drugs.
    Touboul P
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():535-9. PubMed ID: 2275885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can antiarrhythmic agents be selected based on mechanism of action?
    Lau W; Newman D; Dorian P
    Drugs; 2000 Dec; 60(6):1315-28. PubMed ID: 11152014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The experimental anti-arrhythmia properties of the histamine H1 receptor blockader fencarol].
    Iakovlev GM; Skorobogatov VI; Svistov AS; Mironova MI
    Farmakol Toksikol; 1991; 54(5):25-7. PubMed ID: 1686869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy with and assessment of class III antiarrhythmic agents in different patient populations.
    Podrid PJ
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S44-58. PubMed ID: 1279309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ; Markham A
    Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.
    Phillips GB; Morgan TK; Lumma WC; Gomez RP; Lind JM; Lis R; Argentieri T; Sullivan ME
    J Med Chem; 1992 Feb; 35(4):743-50. PubMed ID: 1347318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The anti-arrhythmic activity of quinuclidine derivatives].
    Svistov AS; Skorobogatov VI
    Eksp Klin Farmakol; 1994; 57(5):20-1. PubMed ID: 7696896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.